Japanese Knotweed.

Japanese knotweed root is the commercial source of nearly all supplemental trans-resveratrol, which is extracted and standardised from it. Taking both is the same molecule twice, not two additive actions.

Pterostilbene is the dimethylated stilbene relative of resveratrol, with the same sirtuin and Nrf2 targets but far less first pass conjugation. Pairing them gives one fast clearing and one long lingering stilbene on the same pathway.

Quercetin competes with resveratrol for the sulfotransferase and UGT enzymes that conjugate it in the gut wall and liver. Occupying those enzymes leaves more free stilbene in circulation.

Piperine slows glucuronidation, the dominant route by which resveratrol is inactivated before it reaches the bloodstream. Co-dosing raises the peak and total exposure of the stilbene fraction.

Sirtuins consume NAD+ every time they act, and resveratrol from knotweed pushes sirtuin activity up. An NAD+ precursor supplies the cosubstrate that the activated enzyme spends.

NR raises the cellular NAD+ pool through the salvage route, and the stilbenes in knotweed increase demand on that pool by stimulating sirtuin activity. Activator plus substrate is the pairing logic.

Fisetin and resveratrol both act on senescent cell signalling and on Nrf2 driven antioxidant transcription, through partly different upstream targets. The outcome overlaps where the target does not.

Spermidine drives autophagy by inhibiting the acetyltransferase EP300, and resveratrol reaches the same endpoint through sirtuin mediated deacetylation. Two arms of the same acetylation balance.

Grape seed supplies oligomeric proanthocyanidins while knotweed supplies stilbenes, two different polyphenol families with different absorption profiles and metabolite fates. Blending them widens the polyphenol pool rather than deepening one.

Stilbenes and the tannin fraction of knotweed root bind non-heme iron in the gut and lower the absorbed share. Space the iron dose away from the extract.

Resveratrol dampens platelet aggregation through COX and thromboxane signalling, and long chain omega-3s shift the same eicosanoid balance. The effects add, which is worth flagging around surgery or anticoagulant use.

Both silymarin flavonolignans and stilbenes such as resveratrol are heavily glucuronidated and sulfated in the intestinal wall and liver. Taken together they draw on the same conjugation capacity, which can raise the free fraction of either. This is a pharmacokinetic interaction inferred from established metabolism rather than a measured pair.

Catechins and stilbenes are both substrates and inhibitors of SULT1A1 and several UGT isoforms. Co-dosing can slow conjugation of one by the other, which changes exposure without changing the dose on the label. Polyphenol stacking is common in practice and this is the interaction worth knowing about.

Curcuminoids and stilbenes are both cleared largely by glucuronidation and sulfation, and both have low free plasma levels as a result. Combining them loads the same clearance route. The direction of the net effect depends on doses and timing and has not been measured for this pair.

Luteolin inhibits SULT1A1 in laboratory systems, and stilbene sulfation runs through the same enzyme. In principle that raises unconjugated resveratrol exposure from a knotweed extract. The evidence base here is in vitro and does not establish what happens after a normal oral dose.

Apigenin behaves like luteolin as a sulfotransferase inhibitor in cell-free and cell systems. Paired with a stilbene-standardised knotweed extract it may shift the conjugated to free ratio. Treated as a laboratory-level observation, not a human finding.

Phenolic compounds that quench a radical become a phenoxyl radical themselves, and ascorbate can reduce that species back to the parent phenol. This is standard antioxidant network chemistry and applies to the stilbenes and anthraquinones in knotweed root. It describes a chemical relationship in solution, not a demonstrated clinical benefit.

Tocopherols work in the lipid phase of membranes while polyphenols act mainly in the aqueous phase and at membrane surfaces. The two occupy different compartments of the same redox network. Vitamin E at high intakes also has its own effect on platelet function, which is the reason to be deliberate about stacking it with a stilbene-rich extract.

Garlic organosulfur compounds and stilbenes each reduce platelet aggregation in laboratory and small human work. Combining them is an additive direction rather than an opposing one. Anyone already on a blood-thinning medicine should raise the combination with their clinician before adding it.

Ginkgo terpene lactones antagonise platelet activating factor, and stilbenes reduce aggregation by a separate route. The two point the same way. Flagged so a formulator does not stack several antiplatelet botanicals without noticing.

Nattokinase is a fibrinolytic serine protease, while knotweed stilbenes act on platelets. Their effects sit on the same axis without sharing a mechanism. This is a caution row rather than a recommendation to combine.

Bromelain has been reported to reduce platelet aggregation alongside its proteolytic action. Stacked with a stilbene-rich root extract the direction is additive. The supporting work is small and mostly laboratory-based.

Salicin from willow bark is converted to salicylate, which inhibits platelet cyclooxygenase. Stilbenes act on platelets through separate pathways. Combining them is additive and is the kind of stacking that should be visible on a label rather than incidental.

Polyphenols with adjacent hydroxyl groups bind divalent metal cations in the gut lumen, which is the same chemistry behind the iron interaction already recorded for this herb. Zinc is subject to the same binding. Separating a mineral dose from a polyphenol-rich extract by a couple of hours is the usual practical answer.

Knotweed root carries phenolics and, like many rhizomes, oxalate, both of which form insoluble complexes with calcium in the gut. That lowers the fraction of a co-taken calcium dose that is available. The interaction is at the level of gut chemistry rather than systemic.

Much of the stilbene content of knotweed root exists as polydatin, the glucoside of resveratrol, which must be deglycosylated before the aglycone is absorbed. Intestinal bacteria carrying beta-glucosidase activity perform this conversion alongside host enzymes. Which species do it and how much varies between people, so the effect is a plausible one rather than a dependable one.

Lactobacillus plantarum strains commonly express beta-glucosidase, the enzyme class that releases resveratrol from its glucoside. That step sits upstream of absorption of the aglycone. Strain-level differences are large, so this is species-level reasoning and not a claim about any particular product.

St John's wort is a well-documented inducer of CYP3A4 and P-glycoprotein, while stilbenes act as mild inhibitors of several CYP isoforms in laboratory work. Stacked together they pull drug metabolism in opposite directions in an unpredictable way. Both belong on a medication review rather than in a casual stack.

Berberine is a CYP3A4 substrate and a P-glycoprotein inhibitor in laboratory systems, and stilbenes interact with the same handling. The combination has a real potential to shift exposure of either compound or of a co-taken medicine. Nothing has measured the pair in people.